Klinikum der Universitaet Muenchen AöR
- Address
- Pettenkoferstrasse 8a, Ludwigsvorstadt-Isarvorstadt, 80336 Munich, Germany
Cardiovascular Diseases
The institute is conducting research aimed at improving outcomes after acute ischemic stroke and high‑risk transient ischemic attacks, exploring new strategies to lower the risk of subsequent vascular events.
- Evaluation of novel anticoagulant therapy for stroke prevention
- Strategies to reduce recurrent ischemic events
- Patient‑focused assessments of post‑stroke recovery
These studies are carried out at Klinikum der Universitaet Muenchen AöR, bringing together a large team of investigators to advance cardiovascular care.
Mental Disorders
Research at the department focuses on various forms of dementia, including Alzheimer disease, with efforts to refine diagnostic tools such as amyloid PET imaging and to evaluate their impact on patient and caregiver outcomes.
- Amyloid PET imaging for early detection of Alzheimer’s disease
- Differentiation of vascular and neurodegenerative dementias
- Assessment of patient‑centered benefits of advanced diagnostics
The work is embedded within the broader mission of Klinikum der Universitaet Muenchen AöR to improve mental health care through innovative research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 27 therapeutic areas and 15 of 699 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 640 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 173 by active trials.
- 1AstraZeneca AB14active
lock +172 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB34trials
lock +100 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum der Universitaet Muenchen AöR
lock Showing 1 of 600 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 699 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 37 | Unknown | 2015-07-16 | 2026-06-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.